The damage starts early on in the gut, not the liver itself
In the intricate conversation between what we eat, the microbes we host, and the organs that sustain us, Singaporean researchers have found a new interpreter: a gut protein that quietly signals the liver's future before disease ever announces itself. Scientists at Nanyang Technological University have identified angiopoietin-like 4 as a biological forewarning of fatty liver disease, detectable not in blood but in stool, years before symptoms emerge. The discovery reframes fatty liver not as a liver problem alone, but as a story that begins in the gut — and one that, with the right tools, may now be interrupted before its most damaging chapters unfold.
- Fatty liver disease is advancing silently through 30–40% of Singaporeans, most of whom carry no symptoms and receive no warning from standard blood tests.
- The newly identified gut protein creates a 'leaky gut' that lets bacteria migrate directly into the liver, triggering inflammation and fat accumulation — a mechanism that was hiding in plain sight.
- Stool samples, already collected in Singapore's national colorectal screening program, can detect this protein biomarker far earlier than blood tests, offering a non-invasive path to early intervention.
- Adding the angiopoietin-like 4 test to existing infrastructure requires only standard PCR equipment, making mass screening through the Healthier SG program a realistic near-term possibility.
- International validation efforts and a miniaturized lab-on-a-chip device are already in development, pointing toward a future where a single stool sample screens for multiple serious conditions at once.
Researchers at Nanyang Technological University have identified a gut protein — angiopoietin-like 4 — that acts as a biological bridge between diet, gut bacteria, and liver health. When elevated, the protein makes the gut wall abnormally porous, allowing bacteria to migrate into the liver, where they provoke inflammation and fat accumulation. The team, led by associate professor Andrew Tan at the Lee Kong Chian School of Medicine, spent three to four years analyzing stool samples from thousands of patients across Singapore, Thailand, China, and India — countries chosen precisely because their contrasting diets would illuminate how food shapes gut bacteria and, ultimately, liver disease.
What distinguishes the finding is not only the mechanism but the means of detection. Blood tests, the traditional tool for assessing liver health, routinely miss the disease in its earliest stages. The research team found that stool samples offer a far more reliable window into the gut-liver relationship — catching the protein biomarker before serious illness takes hold. Doctoral student and principal investigator Damien Chua noted that the conventional view treated fatty liver as a liver problem; the new evidence shows the damage originates in the gut, well before it reaches liver tissue.
The urgency is real. Singapore's non-alcoholic fatty liver disease burden is projected to grow from 1.49 million cases in 2019 to 1.8 million by 2030, with an estimated 30–40% of the population at risk. Most carry the condition without knowing it, showing no symptoms and no abnormal enzyme levels. Tan envisions folding the stool-based test into Singapore's Healthier SG program, which already collects fecal samples for colorectal cancer screening. Detecting angiopoietin-like 4 would require no new infrastructure — standard PCR machines found in most clinical labs are sufficient, and a single sample could screen for multiple conditions simultaneously.
Published in Nature Communications in May 2026, the research is being validated further through collaborations in China and Thailand, while NTU engineers develop a microfluidic lab-on-a-chip version of the test for broader deployment. Tan also noted that the findings complement recent National University Hospital research linking genetic and metabolic factors to liver cancer in fatty liver patients — together suggesting a layered screening approach: blood for genetic risk, stool for gut-liver dynamics. The clinical path ahead remains to be traveled, but the infrastructure to walk it is already largely in place.
Researchers at Nanyang Technological University have identified a gut protein that functions as a biological messenger between what you eat, the bacteria living inside you, and the health of your liver. The discovery emerged from a multi-year investigation that examined stool samples from thousands of patients across Singapore, Thailand, China, and India, revealing that elevated levels of this protein—angiopoietin-like 4—correlate with the later development of fatty liver disease.
The protein's role is surprisingly direct. When present in high concentrations, it makes the gut wall abnormally porous, creating what researchers call a leaky gut. This breach allows bacteria to migrate from the intestines directly into the liver, where they trigger inflammation and cause fat to accumulate in liver tissue. The team, led by associate professor Andrew Tan at the Lee Kong Chian School of Medicine, spent three to four years assembling data from patient cohorts in three countries with distinctly different dietary patterns, reasoning that diet shapes gut bacteria composition and therefore would reveal how food choices ultimately affect liver function.
What makes this finding significant is not just the mechanism itself, but the method of detection. Doctors have traditionally relied on blood tests to assess liver health, measuring enzyme levels that indicate damage. Yet these markers often fail to catch the disease in its earliest stages. The research team discovered that stool samples provide a far more reliable window into the gut-liver relationship. Damien Chua, a doctoral student and principal investigator on the project, explained that the conventional understanding treated fatty liver as primarily a liver problem. The new evidence shows the damage originates earlier, in the gut itself, before it ever manifests as liver disease. By testing fecal material rather than blood, researchers can detect the protein biomarker and identify risk before serious illness takes hold.
The timing of this discovery matters urgently for Singapore. Non-alcoholic fatty liver disease has become a growing public health burden, with projections showing cases rising from approximately 1.49 million in 2019 to 1.8 million by 2030. The disease is particularly insidious because most people carrying it experience no symptoms and show no elevation in liver enzymes—meaning they remain unaware they are at risk. Current estimates suggest between 30 and 40 percent of Singaporeans may develop fatty liver disease at some point, a prevalence that carries enormous implications for healthcare costs and quality of life.
Tan envisions integrating the stool-based biomarker test into Singapore's Healthier SG program, a national initiative that emphasizes prevention over reactive treatment. The logistics are already in place. The Healthier SG screening protocol already collects stool samples through the fecal immunochemical test, a non-invasive tool designed to detect early signs of colorectal cancer. Adding a test for the angiopoietin-like 4 protein would require minimal additional infrastructure—the biomarker can be detected using standard PCR machines found in most clinical laboratories. A single stool sample could then be analyzed for multiple conditions simultaneously, much like how a single blood draw can reveal multiple markers of health.
The research, published in Nature Communications in May 2026, represents a collaboration that extends beyond Singapore's borders. Researchers are working with organizations in China and Thailand to validate the findings further, examining how the biomarker changes before and after treatment interventions. Meanwhile, engineers at NTU are developing a microfluidic device version of the test, a miniaturized laboratory-on-a-chip approach that could make screening even more accessible and suitable for deployment across diverse healthcare settings.
Tan emphasized that this work complements recent findings from the National University Hospital, which identified genetic and metabolic risk factors for liver cancer in people with fatty liver disease. Together, the studies suggest a comprehensive approach: screening for genetic predisposition and metabolic conditions through blood work, while simultaneously monitoring gut health through stool analysis. Early detection at the gut stage, before the disease becomes established in liver tissue, opens a window for intervention—dietary changes, targeted therapies, or lifestyle modifications that might prevent progression to more serious liver conditions including cirrhosis and hepatocellular carcinoma. The path from discovery to clinical practice remains ahead, but the framework for implementation already exists.
Notable Quotes
The damage starts early on in the gut, not the liver itself— Damien Chua, LKCMedicine doctoral student and principal investigator
Looking at stools is an easier way for monitoring patients than waiting for liver damage to show up in blood tests— Andrew Tan, associate professor at Lee Kong Chian School of Medicine
The Hearth Conversation Another angle on the story
Why does it matter that we can detect this protein in stool rather than blood?
Because blood tests measure damage that's already happened—elevated enzymes mean the liver is already inflamed. This protein in stool tells you the gut is breaking down before the liver gets sick. You're catching the problem at the source.
So the gut is the real culprit here, not the liver itself?
Not a culprit exactly, but the starting point. The liver doesn't fail on its own. The gut becomes porous, bacteria leak through, and that's what triggers the cascade. If you can see that leakiness early, you can intervene before fat accumulates.
How does diet fit into this?
Diet shapes which bacteria live in your gut. Different bacteria produce different metabolites and proteins. This particular protein, angiopoietin-like 4, gets elevated when your diet and bacterial community are out of balance. That's why they studied three countries with different eating patterns—to see how universal the pattern is.
If 30 to 40 percent of Singaporeans have this disease, why isn't it a bigger crisis?
Because most people don't know they have it. They feel fine. Their blood work looks normal. By the time symptoms appear, the damage is often irreversible. A simple stool test could change that entirely.
What's the practical next step?
They're working to fit this test into the existing Healthier SG screening program. People are already giving stool samples for colorectal cancer screening. Adding one more analysis to that same sample costs almost nothing and could catch fatty liver disease years before it becomes serious.
Is this test ready for hospitals now?
Not quite. They're still validating it across different populations and working on a miniaturized device version. But the science is solid and published in Nature Communications. The infrastructure to run it already exists in most labs. It's more about integration than invention at this point.